T. Rowe Price Associates
AKTS

T. Rowe Price Associates’s Aktis Oncology AKTS Stock Holding History

T. Rowe Price Associates’s Portfolio AKTS Stock Details AKTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.6M Sell
763,499
-800,697
-51% -$16.4M ﹤0.01% 1086
2026
Q1 		$28M Buy
+1,564,196
New +$30.4M ﹤0.01% 949

Other funds holding AKTS

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

T. Rowe Price Associates's AKTS Position: Q2 2026 in Review

T. Rowe Price Associates reduced its Aktis Oncology (AKTS) stake by 51% in Q2 2026, selling an estimated $16.4M and leaving 763,499 shares worth $24.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1086.

T. Rowe Price Associates first reported a position in AKTS in Q1 2026 and has held it in 2 quarters since. The position peaked at $28M in Q1 2026. 114 funds tracked by Wall St. Rank hold AKTS as of Q2 2026.

  • T. Rowe Price Associates held 763,499 shares of Aktis Oncology worth $24.6M as of Q2 2026.
  • T. Rowe Price Associates sold 800,697 Aktis Oncology shares in Q2 2026, an estimated $16.4M.
  • Aktis Oncology made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1086 holding.
  • T. Rowe Price Associates first reported a position in Aktis Oncology in Q1 2026 and has held it in 2 quarters since.
  • T. Rowe Price Associates's Aktis Oncology position peaked at $28M in Q1 2026.
  • 114 funds tracked by Wall St. Rank held Aktis Oncology as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.